1.02
前日終値:
$1.05
開ける:
$1.04
24時間の取引高:
135.91K
Relative Volume:
0.62
時価総額:
$61.78M
収益:
-
当期純損益:
$-64.86M
株価収益率:
-0.9107
EPS:
-1.12
ネットキャッシュフロー:
$-55.66M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
-2.86%
6か月 パフォーマンス:
-55.07%
1年 パフォーマンス:
-65.77%
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
名前
Acumen Pharmaceuticals Inc
セクター
電話
925-368-8508
住所
427 PARK ST., CHARLOTTESVILLE
ABOS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ABOS
Acumen Pharmaceuticals Inc
|
1.02 | 61.78M | 0 | -64.86M | -55.66M | -1.12 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-07-26 | 開始されました | Citigroup | Buy |
2023-12-12 | 開始されました | Deutsche Bank | Buy |
2023-07-20 | 再開されました | BofA Securities | Buy |
2023-05-18 | 開始されました | Cantor Fitzgerald | Overweight |
2022-07-15 | 開始されました | BTIG Research | Buy |
2022-06-30 | 開始されました | H.C. Wainwright | Buy |
2022-01-21 | アップグレード | BofA Securities | Neutral → Buy |
2021-07-26 | 開始されました | BofA Securities | Neutral |
2021-07-26 | 開始されました | Credit Suisse | Outperform |
2021-07-26 | 開始されました | Stifel | Buy |
2021-07-26 | 開始されました | UBS | Buy |
すべてを表示
Acumen Pharmaceuticals Inc (ABOS) 最新ニュース
Halozyme to Participate at Upcoming Investor Conferences - The Malaysian Reserve
FY2025 EPS Estimates for ABOS Reduced by Cantor Fitzgerald - Defense World
Dimensional Fund Advisors LP Purchases 41,460 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Acumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug development - MSN
Acumen Pharmaceuticals’ Earnings Call Highlights Progress in Alzheimer’s Treatment - TipRanks
Tower Research Capital LLC TRC Purchases 16,714 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Transcript : Acumen Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2025 Earnings Call Transcript - Insider Monkey
Barclays PLC Raises Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Barclays PLC Raises Stock Holdings in Babcock & Wilcox Enterprises, Inc. (NYSE:BW) - Defense World
Acumen Pharmaceuticals Q1 2025 Financial Update - TipRanks
ABOS Reports Decline in Cash Reserves to Support Operations | AB - GuruFocus
Earnings call transcript: Acumen Pharmaceuticals Q1 2025 financial results and stock gains - Investing.com Nigeria
Acumen (ABOS) Advances in Alzheimer's Treatment Study | ABOS Sto - GuruFocus
ACUMEN PHARMACEUTICALS Earnings Results: $ABOS Reports Quarterly Earnings - Nasdaq
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Acumen Pharmaceuticals (ABOS) to Release Earnings on Tuesday - Defense World
Acumen Pharmaceuticals Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference - The Manila Times
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - The Manila Times
Upcoming Earnings: Alzheimer's Drug Developer Acumen Pharmaceuticals Reports Q1 Results May 13 - Stock Titan
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - The Malaysian Reserve
Renaissance Technologies LLC Cuts Stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Halozyme to Report First Quarter 2025 Financial and Operating Results - Yahoo Finance
JPMorgan Chase & Co. Has $1.61 Million Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
ABOS stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
ABOS stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Finansavisen
Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) & Precision BioSciences (NASDAQ:DTIL) - The AM Reporter
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting - The Manila Times
Game-Changing Trial Screening Method: Acumen Advances Alzheimer's Research with pTau217 Innovation - Stock Titan
Charles Schwab Investment Management Inc. Acquires 18,004 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
What is HC Wainwright’s Forecast for ABOS FY2029 Earnings? - Defense World
FY2029 Earnings Forecast for ABOS Issued By HC Wainwright - The AM Reporter
UBS Group Lowers Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $4.00 - Defense World
Acumen Pharmaceuticals outlines ALTITUDE AD Phase 2 plans and late 2026 data timeline - MSN
HC Wainwright Has Lowered Expectations for Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Cut to $11.00 by Analysts at HC Wainwright - The AM Reporter
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2024 Earnings Call Transcript - Insider Monkey
Acumen Pharmaceuticals’ Earnings Call: Progress Amid Challenges - TipRanks
Bank of America Securities Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
UBS Cuts Price Target on Acumen Pharmaceuticals to $4 From $6, Keeps Buy Rating - MarketScreener
Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Acumen Pharmaceuticals Advances Alzheimer’s Treatment Efforts - TipRanks
Earnings call transcript: Acumen Pharmaceuticals Q4 2024 focuses on Alzheimer’s innovations - Investing.com
Acumen Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights - The Manila Times
Acumen's $231M War Chest Powers Breakthrough Alzheimer's Drug Development - Stock Titan
Acumen Pharmaceuticals Inc (ABOS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):